SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
Rhea-AI Summary
SI-BONE (Nasdaq: SIBN) will present at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026. Management will host a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.
Live audio will stream via the company’s Investors site and a registration link; the webcast will be archived for at least 90 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
SIBN is up 2.34% with elevated volume, while key peers show mixed moves: AXGN up 3.4%, OFIX up 0.82%, TNDM down 0.84%, AVNS down 0.13%, and ZIMV flat. This points to stock-specific interest rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 02 | Earnings date set | Neutral | -0.7% | Announcement of Q4 and full-year 2025 earnings release and call timing. |
| Jan 12 | Prelim 2025 revenue | Positive | -12.6% | Preliminary Q4 and full-year 2025 revenue and cash metrics with solid growth. |
| Nov 18 | Investor conference | Neutral | +1.3% | Presentation and fireside chat at Piper Sandler 37th Annual Healthcare Conference. |
| Nov 10 | Q3 2025 earnings | Positive | -0.6% | Strong Q3 revenue growth, margin improvement, cash generation, and raised guidance. |
| Nov 10 | Q2 2025 earnings | Positive | -0.6% | Robust Q2 revenue growth, margin strength, higher guidance, and positive EBITDA outlook. |
Recent history shows several positive financial updates (preliminary revenue, raised guidance) followed by negative or muted price reactions, indicating a tendency for shares to lag or sell off on good news.
Over the last few months, SI-BONE reported multiple financial and investor-relations milestones. In Q3 2025, it delivered $48.7M revenue with strong double-digit growth and raised full-year 2025 guidance to $198M–$200M. Preliminary 2025 results on Jan 12, 2026 highlighted ~$200.8–$200.9M worldwide revenue and cash of $147.7M, yet the stock fell 12.57%. The company also regularly announces earnings dates and conference presentations, like the Piper Sandler event on Dec 2, 2025, reinforcing an active investor-engagement strategy that today’s TD Cowen appearance continues.
Market Pulse Summary
This announcement highlights SI-BONE’s participation in a major health care conference, with a fireside chat on March 2, 2026 and a webcast archived for at least 90 days. It continues a pattern of frequent investor outreach alongside prior growth-focused updates, including raised 2025 guidance and solid revenue expansion. Investors may watch upcoming earnings on February 23, 2026, ongoing institutional ownership disclosures, and any new operating metrics shared at conferences for signals on execution and demand trends.
AI-generated analysis. Not financial advice.
SANTA CLARA, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Management will be hosting a fireside chat on Monday, March 2, 2026, at 7:30 a.m. Pacific Time/ 10:30 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/hkU3gw9TuYE3fDbRaRPY9r. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 140,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 180 peer reviewed publications.
For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.
SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.
Marnelli.delcastillo@si-bone.com